November 20th 2024
Under the collaboration, the companies will create and test circVec DNA–LNP formulations with an eye toward potential therapeutic applications.
Lonza and Moderna to Expand Their COVID-19 Vaccine Drug Substance Manufacturing Collaboration
June 2nd 2021The companies are expanding their collaboration to extend the drug substance manufacturing of Moderna’s COVID-19 vaccine with the addition of a new manufacturing line at Lonza’s Geleen, Netherlands, site.
Moderna and Samsung Biologics Partner on Fill/Finish Manufacturing of Moderna’s COVID-19 Vaccine
May 24th 2021Samsung Biologics plans to support the production of hundreds of millions of doses of Moderna’s vaccine to supply to markets outside of the United States beginning in the third quarter of 2021.
Bristol Myers Squibb Enters into Agreement with Agenus for Up to $1.56 Billion
May 19th 2021Bristol Myers Squibb has entered into a definitive agreement with Agenus for a global exclusive license to Agenus’ proprietary bispecific antibody program, AGEN1777, that blocks TIGIT and a second undisclosed target.
Biogen and Capsigen to Develop Novel AAV Capsids for up to $1.37 Billion
May 12th 2021Biogen and Capsigen have entered into a strategic research collaboration to engineer novel AAV capsids to deliver gene therapies that address the underlying genetic causes of various central nervous system and neuromuscular disorders.
Sterling Pharma Solutions and OncoTEX to Develop Novel Treatment Against Ovarian Cancer
May 11th 2021Sterling Pharma Solutions and OncoTEX have entered into a clinical development agreement for the manufacturing of OncoTex’s novel platinum-resistant oncology drug candidate, OxaliTEX, for use in clinical trials.
Moderna to Supply Up to 500 Million COVID-19 Vaccine Doses to Low- and Middle-Income Countries
May 4th 2021Moderna has entered into an agreement with Gavi, the Vaccine Alliance to supply up to 500 million doses of its COVID-19 vaccine to the 92 Gavi COVAX Advance Market Commitment low- and middle-income countries.
Catalent Enters into Gene Therapy Manufacturing Collaboration with AavantiBio
April 28th 2021Under the terms of the agreement, Catalent will handle the process development and CGMP manufacturing of AavantiBio’s adeno-associated viral vector-based therapeutic candidate for use in clinical trials in the US and Europe.
DNA Script to Team up With Moderna for Vaccine and Therapeutic Manufacturing for DARPA
April 27th 2021With a $5 million grant from DARPA, DNA Script and Moderna will develop a prototype for rapid mobile manufacturing of vaccines and therapeutics as part of the DARPA’s Nucleic Acids On-Demand World-Wide program.